Novel Effective Non-invasive Clinical Treatment for Persistent High-Risk
Human Papillomavirus Infection
Abstract
High-risk human papillomavirus (hrHPV) is the major cause of cervical
cancer. The majority of hrHPV infections resolve spontaneously. However,
when hrHPV escapes host’s immune system and establishes persistent
infection in basal keratinocytes, self-clearance of the infection
becomes exactly difficult, and medical intervention is urgently needed
to eradicate viral infection and prevent cervical cancer. This review
aimed to summarize our findings and achievements on REBACIN®—an
anti-viral biologic with low cost, no cold chain and no hospitalization,
and demonstrated that REBACIN® exhibits potent efficacy in clearing
persistent hrHPV infections, promotes regression of associated lesions
via targeted inhibition of viral E6/E7 oncogenes.